Anti-Obesity Drugs Show Significant Promise for Improving Liver Health in MASLD
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as NAFLD, is a prevalent chronic liver condition characterized by excessive fat accumulation in the liver, often progressing to fibrosis, cirrhosis, and liver cancer. It is strongly linked to obesity, type 2 diabetes, and metabolic syndrome, posing a major global health burden with limited approved pharmacological treatments. This updated review synthesizes the latest evidence on the efficacy and safety of various anti-obesity medications in improving MASLD outcomes, identifying optimal therapeutic strategies and knowledge gaps.
Results
The review consistently found that several anti-obesity drugs significantly improve MASLD markers, often beyond the benefits of weight loss alone. GLP-1 receptor agonists demonstrated substantial reductions in liver fat content, with semaglutide showing up to a 30% relative reduction in liver fat fraction in some studies, and liraglutide achieving MASLD resolution in 39% of patients compared to 9% with placebo (p<0.001). Dual GLP-1/GIP receptor agonists, such as tirzepatide, emerged as particularly potent, with studies reporting MASLD resolution without worsening fibrosis in up to 74% of patients at higher doses (e.g., 15 mg once weekly) and a mean reduction in liver fat content of 81% from baseline. SGLT2 inhibitors also showed benefits, with dapagliflozin and empagliflozin leading to significant reductions in liver enzymes (e.g., ALT decreased by 20-30%) and modest improvements in liver steatosis, though their direct impact on fibrosis was less pronounced than GLP-1 agonists. Overall, these agents not only facilitated weight loss (ranging from 5% to 20% of body weight) but also directly targeted hepatic pathology, with a generally favorable safety profile, though gastrointestinal side effects were common. > The most impactful finding was the high rate of MASLD resolution and fibrosis improvement achieved by GLP-1 and dual GLP-1/GIP receptor agonists, positioning them as leading candidates for pharmacological treatment.
Why It Matters
This comprehensive review highlights the transformative potential of anti-obesity drugs in managing and potentially reversing MASLD, moving beyond mere lifestyle interventions to address underlying liver pathology. The strong evidence for GLP-1 receptor agonists and dual GLP-1/GIP agonists in achieving MASLD resolution and fibrosis improvement underscores their critical role in future treatment paradigms. These findings strongly support the integration of these pharmacological agents into clinical guidelines for MASLD, potentially leading to widespread clinical adoption and significantly improved patient outcomes. Further Phase III clinical trials are warranted to confirm long-term efficacy and safety, especially in diverse patient populations and those with advanced fibrosis, paving the way for regulatory approvals.